Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

BACKGROUND: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Anholm, Christian, Kumarathurai, Preman, Jürs, Anders, Pedersen, Lene Rørholm, Nielsen, Olav Wendelboe, Kristiansen, Ole Peter, Fenger, Mogens, Holst, Jens Juul, Madsbad, Sten, Sajadieh, Ahmad, Haugaard, Steen Bendix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543623/
https://www.ncbi.nlm.nih.gov/pubmed/31164926
http://dx.doi.org/10.1186/s13098-019-0438-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543623/
https://www.ncbi.nlm.nih.gov/pubmed/31164926
http://dx.doi.org/10.1186/s13098-019-0438-6

Ejemplares similares